ALNOV logo

Novacyt S.A. Stock Price

ENXTPA:ALNOV Community·€30.7m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

ALNOV Share Price Performance

€0.44
-0.17 (-28.37%)
€0.44
-0.17 (-28.37%)
Price €0.44

ALNOV Community Narratives

There are no narratives available yet.

Snowflake Analysis

Flawless balance sheet and fair value.

2 Risks
2 Rewards

Novacyt S.A. Key Details

UK£19.5m

Revenue

UK£8.2m

Cost of Revenue

UK£11.2m

Gross Profit

UK£39.7m

Other Expenses

-UK£28.5m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-0.40
57.70%
-146.48%
0%
View Full Analysis

About ALNOV

Founded
2006
Employees
234
CEO
Lyn Rees
WebsiteView website
www.novacyt.com

Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. It operates in the United Kingdom, France, Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company was incorporated in 2006 and is based in Le Vésinet, France.

Recent ALNOV News & Updates

Recent updates

No updates